TALi Digital (ASX:TD1)
TALi is a pioneering digital therapeutic company developing solutions to assess, monitor and enhance cognitive function and treat cognitive impairment. TALi’s frontline solution addresses the unmet global need for early detection and safe treatment of attention deficits during early childhood. Our team of scientists, clinicians, developers and customer-focused individuals are on a mission to strengthen the attention of children globally, delivering lasting benefits in their cognitive development.
TALi Health is a 100% owned subsidiary of TALi Digital Limited (ASX: TD1), which is an Australian medical technology company listed on the Australian Securities Exchange. TALi Digital’s core focus is the pioneering development of clinically-validated software solutions that assess and improve.
Total revenue and income $548,905
Net loss $4,858,273
Net cash at bank $2.73 million as at 30 June 2021 (vs $3.95 million as at 30 June 2020)
Strategic Licensing Agreement with …
TALi Digital Ltd (ASX: TD1, “TALi” or “the Company”) will provide a live video webcast and Q&A discussion hosted by Managing Director, Mr Glenn Smith today at 12.30pm AES…